CTD Holdings to Host Webinar to Provide Update on Trappsol(R) Cyclo(TM) Drug Development Program for Treatment of Niemann-Pick Disease Type C

ALACHUA, FL–(Marketwired – May 16, 2017) – CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will host a webinar to provide details of the Company’s recently initiated Phase I clinical trial in the U.S. and Phase I/II clinical trial in the EU, both evaluating CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C (NPC). NPC is a rare and fatal genetic disease that damages the brain, lung, liver, spleen, and other organs.